SARS-CoV-2 BA.1 variant is neutralized by vaccine booster-elicited serum but evades most convalescent serum and therapeutic antibodies

Sabrina Lusvarghi, Simon D Pollett, Sabari Nath Neerukonda, Wei Wang, Richard Wang, Russell Vassell, Nusrat J Epsi, Anthony C Fries, Brian K Agan, David A Lindholm, Christopher J Colombo, Rupal Mody, Evan C Ewers, Tahaniyat Lalani, Anuradha Ganesan, Emilie Goguet, Monique Hollis-Perry, Si'Ana A Coggins, Mark P Simons, Leah C Katzelnick, Gregory Wang, David R Tribble, Lisa Bentley, Ann E Eakin, Christopher C Broder, Karl J Erlandson, Eric D Laing, Timothy H Burgess, Edward Mitre, Carol D Weiss, Sabrina Lusvarghi, Simon D Pollett, Sabari Nath Neerukonda, Wei Wang, Richard Wang, Russell Vassell, Nusrat J Epsi, Anthony C Fries, Brian K Agan, David A Lindholm, Christopher J Colombo, Rupal Mody, Evan C Ewers, Tahaniyat Lalani, Anuradha Ganesan, Emilie Goguet, Monique Hollis-Perry, Si'Ana A Coggins, Mark P Simons, Leah C Katzelnick, Gregory Wang, David R Tribble, Lisa Bentley, Ann E Eakin, Christopher C Broder, Karl J Erlandson, Eric D Laing, Timothy H Burgess, Edward Mitre, Carol D Weiss

Abstract

The rapid spread of the highly contagious Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) along with its high number of mutations in the spike gene has raised alarms about the effectiveness of current medical countermeasures. To address this concern, we measured the neutralization of the Omicron BA.1 variant pseudovirus by postvaccination serum samples after two and three immunizations with the Pfizer/BioNTech162b2 SARS-CoV-2 mRNA (Pfizer/BNT162b2) vaccine, convalescent serum samples from unvaccinated individuals infected by different variants, and clinical-stage therapeutic antibodies. We found that titers against the Omicron variant were low or undetectable after two immunizations and in many convalescent serum samples, regardless of the infecting variant. A booster vaccination increased titers more than 30-fold against Omicron to values comparable to those seen against the D614G variant after two immunizations. Neither age nor sex was associated with the differences in postvaccination antibody responses. We also evaluated 18 clinical-stage therapeutic antibody products and an antibody mimetic protein product obtained directly from the manufacturers. Five monoclonal antibodies, the antibody mimetic protein, three antibody cocktails, and two polyclonal antibody preparations retained measurable neutralization activity against Omicron with a varying degree of potency. Of these, only three retained potencies comparable to the D614G variant. Two therapeutic antibody cocktails in the tested panel that are authorized for emergency use in the United States did not neutralize Omicron. These findings underscore the potential benefit of mRNA vaccine boosters for protection against Omicron and the need for rapid development of antibody therapeutics that maintain potency against emerging variants.

Figures

Fig. 1.
Fig. 1.
Sensitivity of the Omicron variant to neutralization by Pfizer/BNT162b2 vaccinee serum samples. (A) Neutralization assays used lentiviral pseudoviruses bearing SARS-CoV-2 spike proteins from D614G, Delta, or Omicron. Serum samples from 39 healthcare workers were obtained at a mean of 30 ± 11 or 43 ± 17 days after the 2nd or 3rd immunization, respectively. The geometric means titers (GMT), the number of serum samples above threshold (1:40, the lowest dilution tested, dotted lines), and the fold change are indicated. Titers below 1:40 were set at 20 to calculate GMTs. Black arrows indicate fold decrease relative to D614G after the 2nd or 3rd immunization. Purple arrows indicate fold increase for each variant after the 3rd vaccination compared to the 2nd vaccination. Connecting lines indicate serum from the same individual. Demographic information is provided in Table 1. (B) NT50 values are shown by sex after 2nd or 3rd vaccinations. (C) NT50 values are shown by age after 2nd and 3rd vaccinations. (D) NT50 values are shown after 2nd or 3rd vaccination according to anti-N (nucleocapsid protein) seroconversion between 2nd and 3rd vaccinations. Presence of anti-N antibodies suggests prior SARS-CoV-2 infection. (E) Ratio of NT50 values after 3rd versus 2nd immunizations are shown for D614G, Delta, and Omicron. The mean of ratios is shown below each variant. Black squares correspond to D614G, blue triangles correspond to Delta, and red circles correspond to Omicron. Data shown represent two independent experiments each with an intra-assay duplicate. Significance for (A) and (E) was assessed by one-way ANOVA with the Geisser-Greenhouse correction, followed by Tukey’s multiple comparison test. Significance for (B) and (D) was assessed by Kruskal-Wallis test, followed by Dunn’s multiple comparison test. Significance values are indicated as *P < 0.05; **P < 0.01; ***P < 0.001; ns, nonsignificant.
Fig. 2.
Fig. 2.
Sensitivity of the Omicron variant to neutralization by convalescent serum samples. Neutralization assays were performed using convalescent serum samples from individuals infected with genotyped variants from B.1, B.1.2, B.1.1.7, B.1.351, B.1.617.2, AY.14, AY.25, AY.44, AY.47, AY.62, AY.74 or AY.119 lineages (Table 2, tables S1 and S2). B.1 and B.1.2 have no mutations in the receptor binding domain and were therefore considered D614G, whereas some of the AY mutants have additional non-RBD spike mutations relative to B.1.617.2. Titers above threshold (1:40) and fold changes are indicated. Titers below threshold were set as 20 for GMT calculations. Arrows indicate decrease relative to D614G (for D614G, Alpha and Beta serum samples) or Delta (for Delta serum samples). Connecting lines indicate serum from the same individual. Data shown represent two independent experiments, each with an intra-assay duplicate. Squares correspond to D614G, triangles correspond to Delta, and circles correspond to Omicron. Significance was assessed using a Kruskal-Wallis test followed by a Dunn’s post-test. Significance values are indicated as *P < 0.05; **P < 0.01; ***P < 0.001; ns, nonsignificant.
Fig. 3.. Antigenic cartography of convalescent and…
Fig. 3.. Antigenic cartography of convalescent and vaccinee serum samples against D614G, Delta, and Omicron variants.
Antigenic maps were generated from (A) convalescent, (B) 2nd vaccination, or (C) 3rd vaccination serum samples. Convalescent serum samples are shown in open diamonds as follows: B.1 (black), B.1.2 (gray), B.1.1.7 (magenta), B.1.351 (green), AY variants (light blue), and B.1.617.2 (dark blue). Solid gray diamonds correspond to post-vaccination serum. Each grid square (1 antigenic unit) corresponds to a 2-fold dilution in the neutralization assay. Antigenic distance is interpretable in any direction. Black squares correspond to D614G variant. Blue triangles correspond to the Delta variant. Red circles correspond to the Omicron variant. The confidence area of the position of individual viruses or serum sample displayed in the bottom panels was estimated with stress parameter 0.5 and is shown as a rounded shape in the maps.
Fig. 4.
Fig. 4.
Neutralization of the Omicron variant pseudovirus by therapeutic antibodies. (A to C) Neutralization curves against D614G (black) and Omicron (red) are shown for eleven monoclonal neutralizing antibodies (nAb) and one tri-specific antibody mimetic protein (DARPin) (A), five cocktail neutralizing antibody products (B), and two polyclonal antibody preparations (C). (D) IC50 values against D614G and Omicron are shown for all therapeutic antibodies. IC50 values were calculated from two independent experiments, each with an intra-assay duplicate.

References

    1. Corti D., Purcell L. A., Snell G., Veesler D., Tackling COVID-19 with neutralizing monoclonal antibodies. Cell 184, 4593–4595 (2021). 10.1016/j.cell.2021.07.027
    1. Gruell H., Vanshylla K., Tober-Lau P., Hillus D., Schommers P., Lehmann C., Kurth F., Sander L. E., Klein F., mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant. Nat. Med. 28, 477–480 (2022). 10.1038/s41591-021-01676-0
    1. Planas D., Saunders N., Maes P., Guivel-Benhassine F., Planchais C., Buchrieser J., Bolland W. H., Porrot F., Staropoli I., Lemoine F., Péré H., Veyer D., Puech J., Rodary J., Baele G., Dellicour S., Raymenants J., Gorissen S., Geenen C., Vanmechelen B., Wawina-Bokalanga T., Martí-Carreras J., Cuypers L., Sève A., Hocqueloux L., Prazuck T., Rey F. A., Simon-Loriere E., Bruel T., Mouquet H., André E., Schwartz O., Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature 602, 671–675 (2022). 10.1038/s41586-021-04389-z
    1. Liu L., Iketani S., Guo Y., Chan J. F., Wang M., Liu L., Luo Y., Chu H., Huang Y., Nair M. S., Yu J., Chik K. K., Yuen T. T., Yoon C., To K. K., Chen H., Yin M. T., Sobieszczyk M. E., Huang Y., Wang H. H., Sheng Z., Yuen K. Y., Ho D. D., Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature 602, 676–681 (2022). 10.1038/s41586-021-04388-0
    1. Garcia-Beltran W. F., St Denis K. J., Hoelzemer A., Lam E. C., Nitido A. D., Sheehan M. L., Berrios C., Ofoman O., Chang C. C., Hauser B. M., Feldman J., Roederer A. L., Gregory D. J., Poznansky M. C., Schmidt A. G., Iafrate A. J., Naranbhai V., Balazs A. B., mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. Cell 185, 457–466.e4 (2022). 10.1016/j.cell.2021.12.033
    1. Andrews N., Stowe J., Kirsebom F., Toffa S., Rickeard T., Gallagher E., Gower C., Kall M., Groves N., O’Connell A. M., Simons D., Blomquist P. B., Zaidi A., Nash S., Iwani Binti Abdul Aziz N., Thelwall S., Dabrera G., Myers R., Amirthalingam G., Gharbia S., Barrett J. C., Elson R., Ladhani S. N., Ferguson N., Zambon M., Campbell C. N. J., Brown K., Hopkins S., Chand M., Ramsay M., Lopez Bernal J., Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. N. Engl. J. Med. NEJMoa2119451 (2022). 10.1056/NEJMoa2119451
    1. Pajon R., Doria-Rose N. A., Shen X., Schmidt S. D., O’Dell S., McDanal C., Feng W., Tong J., Eaton A., Maglinao M., Tang H., Manning K. E., Edara V.-V., Lai L., Ellis M., Moore K. M., Floyd K., Foster S. L., Posavad C. M., Atmar R. L., Lyke K. E., Zhou T., Wang L., Zhang Y., Gaudinski M. R., Black W. P., Gordon I., Guech M., Ledgerwood J. E., Misasi J. N., Widge A., Sullivan N. J., Roberts P. C., Beigel J. H., Korber B., Baden L. R., El Sahly H., Chalkias S., Zhou H., Feng J., Girard B., Das R., Aunins A., Edwards D. K., Suthar M. S., Mascola J. R., Montefiori D. C., SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination. N. Engl. J. Med. 386, 1088–1091 (2022). 10.1056/NEJMc2119912
    1. Dejnirattisai W., Huo J., Zhou D., Zahradník J., Supasa P., Liu C., Duyvesteyn H. M. E., Ginn H. M., Mentzer A. J., Tuekprakhon A., Nutalai R., Wang B., Dijokaite A., Khan S., Avinoam O., Bahar M., Skelly D., Adele S., Johnson S. A., Amini A., Ritter T. G., Mason C., Dold C., Pan D., Assadi S., Bellass A., Omo-Dare N., Koeckerling D., Flaxman A., Jenkin D., Aley P. K., Voysey M., Costa Clemens S. A., Naveca F. G., Nascimento V., Nascimento F., Fernandes da Costa C., Resende P. C., Pauvolid-Correa A., Siqueira M. M., Baillie V., Serafin N., Kwatra G., Da Silva K., Madhi S. A., Nunes M. C., Malik T., Openshaw P. J. M., Baillie J. K., Semple M. G., Townsend A. R., Huang K. A., Tan T. K., Carroll M. W., Klenerman P., Barnes E., Dunachie S. J., Constantinides B., Webster H., Crook D., Pollard A. J., Lambe T., Paterson N. G., Williams M. A., Hall D. R., Fry E. E., Mongkolsapaya J., Ren J., Schreiber G., Stuart D. I., Screaton G. R.; OPTIC Consortium; ISARIC4C Consortium , SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell 185, 467–484.e15 (2022). 10.1016/j.cell.2021.12.046
    1. Carreño J. M., Alshammary H., Tcheou J., Singh G., Raskin A. J., Kawabata H., Sominsky L. A., Clark J. J., Adelsberg D. C., Bielak D. A., Gonzalez-Reiche A. S., Dambrauskas N., Vigdorovich V., Srivastava K., Sather D. N., Sordillo E. M., Bajic G., van Bakel H., Simon V., Krammer F.; PSP-PARIS Study Group , Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. Nature 602, 682–688 (2022). 10.1038/s41586-022-04399-5
    1. Basile K., Rockett R. J., McPhie K., Fennell M., Johnson-Mackinnon J., Agius J. E., Fong W., Rahman H., Ko D., Donavan L., Hueston L., Lam C., Arnott A., Chen S. C. A., Maddocks S., O’Sullivan M. V., Dwyer D. E., Sintchenko V., Kok J., Improved neutralization of the SARS-CoV-2 Omicron variant after Pfizer-BioNTech BNT162b2 COVID-19 vaccine boosting. bioRxiv, 2021.2012.2012.472252 (2021).10.1101/2021.12.12.472252
    1. Mannar D., Saville J. W., Zhu X., Srivastava S. S., Berezuk A. M., Tuttle K. S., Marquez A. C., Sekirov I., Subramaniam S., SARS-CoV-2 Omicron variant: Antibody evasion and cryo-EM structure of spike protein-ACE2 complex. Science 375, 760–764 (2022). 10.1126/science.abn7760
    1. Hoffmann M., Krüger N., Schulz S., Cossmann A., Rocha C., Kempf A., Nehlmeier I., Graichen L., Moldenhauer A. S., Winkler M. S., Lier M., Dopfer-Jablonka A., Jäck H. M., Behrens G. M. N., Pöhlmann S., The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic. Cell 185, 447–456.e11 (2022). 10.1016/j.cell.2021.12.032
    1. Ikemura N., Hoshino A., Higuchi Y., Taminishi S., Inaba T., Matoba S., SARS-CoV-2 Omicron variant escapes neutralization by vaccinated and convalescent sera and therapeutic monoclonal antibodies. medRxiv, 2021.2012.2013.21267761 (2021).10.1101/2021.12.13.21267761
    1. Cameroni E., Bowen J. E., Rosen L. E., Saliba C., Zepeda S. K., Culap K., Pinto D., VanBlargan L. A., De Marco A., di Iulio J., Zatta F., Kaiser H., Noack J., Farhat N., Czudnochowski N., Havenar-Daughton C., Sprouse K. R., Dillen J. R., Powell A. E., Chen A., Maher C., Yin L., Sun D., Soriaga L., Bassi J., Silacci-Fregni C., Gustafsson C., Franko N. M., Logue J., Iqbal N. T., Mazzitelli I., Geffner J., Grifantini R., Chu H., Gori A., Riva A., Giannini O., Ceschi A., Ferrari P., Cippà P. E., Franzetti-Pellanda A., Garzoni C., Halfmann P. J., Kawaoka Y., Hebner C., Purcell L. A., Piccoli L., Pizzuto M. S., Walls A. C., Diamond M. S., Telenti A., Virgin H. W., Lanzavecchia A., Snell G., Veesler D., Corti D., Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature 602, 664–670 (2022). 10.1038/s41586-021-04386-2
    1. Nemet I., Kliker L., Lustig Y., Zuckerman N., Erster O., Cohen C., Kreiss Y., Alroy-Preis S., Regev-Yochay G., Mendelson E., Mandelboim M., Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection. N. Engl. J. Med. 386, 492–494 (2022). 10.1056/NEJMc2119358
    1. Schmidt F., Muecksch F., Weisblum Y., Da Silva J., Bednarski E., Cho A., Wang Z., Gaebler C., Caskey M., Nussenzweig M. C., Hatziioannou T., Bieniasz P. D., Plasma Neutralization of the SARS-CoV-2 Omicron Variant. N. Engl. J. Med. 386, 599–601 (2022). 10.1056/NEJMc2119641
    1. Rössler A., Riepler L., Bante D., von Laer D., Kimpel J., SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons. N. Engl. J. Med. 386, 698–700 (2022). 10.1056/NEJMc2119236
    1. Wilhelm A., Widera M., Grikscheit K., Toptan T., Schenk B., Pallas C., Metzler M., Kohmer N., Hoehl S., Helfritz F. A., Wolf T., Goetsch U., Ciesek S., Reduced Neutralization of SARS-CoV-2 Omicron Variant by Vaccine Sera and monoclonal antibodies. medRxiv, 2021.2012.2007.21267432 (2021).10.1101/2021.12.07.21267432
    1. Lu L., Mok B. W., Chen L. L., Chan J. M., Tsang O. T., Lam B. H., Chuang V. W., Chu A. W., Chan W. M., Ip J. D., Chan B. P., Zhang R., Yip C. C., Cheng V. C., Chan K. H., Jin D. Y., Hung I. F., Yuen K. Y., Chen H., To K. K., Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients. Clin. Infect. Dis. ciab1041 (2021). 10.1093/cid/ciab1041
    1. Cele S., Jackson L., Khoury D. S., Khan K., Moyo-Gwete T., Tegally H., San J. E., Cromer D., Scheepers C., Amoako D. G., Karim F., Bernstein M., Lustig G., Archary D., Smith M., Ganga Y., Jule Z., Reedoy K., Hwa S. H., Giandhari J., Blackburn J. M., Gosnell B. I., Abdool Karim S. S., Hanekom W., von Gottberg A., Bhiman J. N., Lessells R. J., Moosa M. S., Davenport M. P., de Oliveira T., Moore P. L., Sigal A.; NGS-SA; COMMIT-KZN Team , Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature 602, 654–656 (2022). 10.1038/s41586-021-04387-1
    1. Cao Y., Wang J., Jian F., Xiao T., Song W., Yisimayi A., Huang W., Li Q., Wang P., An R., Wang J., Wang Y., Niu X., Yang S., Liang H., Sun H., Li T., Yu Y., Cui Q., Liu S., Yang X., Du S., Zhang Z., Hao X., Shao F., Jin R., Wang X., Xiao J., Wang Y., Xie X. S., Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature 602, 657–663 (2022). 10.1038/s41586-021-04385-3
    1. VanBlargan L. A., Errico J. M., Halfmann P. J., Zost S. J., Crowe J. E. Jr., Purcell L. A., Kawaoka Y., Corti D., Fremont D. H., Diamond M. S., An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. Nat. Med. 28, 490–495 (2022). 10.1038/s41591-021-01678-y
    1. Jackson-Thompson B. M., Goguet E., Laing E. D., Olsen C. H., Pollett S., Hollis-Perry K. M., Maiolatesi S. E., Illinik L., Ramsey K. F., Reyes A. E., Alcorta Y., Wong M. A., Davies J., Ortega O., Parmelee E., Lindrose A. R., Moser M., Graydon E., Letizia A. G., Duplessis C. A., Ganesan A., Pratt K. P., Malloy A. M., Scott D. W., Anderson S. K., Snow A. L., Dalgard C. L., Powers J. H. 3rd, Tribble D., Burgess T. H., Broder C. C., Mitre E., Prospective Assessment of SARS-CoV-2 Seroconversion (PASS) study: An observational cohort study of SARS-CoV-2 infection and vaccination in healthcare workers. BMC Infect. Dis. 21, 544 (2021). 10.1186/s12879-021-06233-1
    1. Laing E. D., Weiss C. D., Samuels E. C., Coggins S. A., Wang W., Wang R., Vassell R., Sterling S. L., Tso M. S., Conner T., Goguet E., Moser M., Jackson-Thompson B. M., Illinik L., Davies J., Ortega O., Parmelee E., Hollis-Perry M., Maiolatesi S. E., Wang G., Ramsey K. F., Reyes A. E., Alcorta Y., Wong M. A., Lindrose A. R., Duplessis C. A., Tribble D. R., Malloy A. M. W., Burgess T. H., Pollett S. D., Olsen C. H., Broder C. C., Mitre E., Durability of Antibody Response and Frequency of SARS-CoV-2 Infection 6 Months after COVID-19 Vaccination in Healthcare Workers. Emerg. Infect. Dis. 28, 828–832 (2022). 10.3201/eid2804.212037
    1. Laing E. D., Sterling S. L., Richard S. A., Epsi N. J., Coggins S., Samuels E. C., Phogat S., Yan L., Moreno N., Coles C. L., Drew M., Mehalko J., Merritt S., Mende K., Munster V., de Wit E., Chung K. K., Millar E. V., Tribble D. R., Simons M. P., Pollett S. D., Esposito D., Lanteri C., Clifton G. T., Mitre E., Burgess T. H., Broder C. C., Antigen-based multiplex strategies to discriminate SARS-CoV-2 natural and vaccine induced immunity from seasonal human coronavirus humoral responses. medRxiv, (2021).10.1101/2021.02.10.21251518
    1. Richard S. A., Pollett S. D., Lanteri C. A., Millar E. V., Fries A. C., Maves R. C., Utz G. C., Lalani T., Smith A., Mody R. M., Ganesan A., Colombo R. E., Colombo C. J., Lindholm D. A., Madar C., Chi S., Huprikar N., Larson D. T., Bazan S. E., English C., Parmelee E., Mende K., Laing E. D., Broder C. C., Blair P. W., Chenoweth J. G., Simons M. P., Tribble D. R., Agan B. K., Burgess T. H.; EPICC COVID-19 Cohort Study Group , COVID-19 Outcomes Among US Military Health System Beneficiaries Include Complications Across Multiple Organ Systems and Substantial Functional Impairment. Open Forum Infect. Dis. 8, ofab556 (2021). 10.1093/ofid/ofab556
    1. Lusvarghi S., Wang W., Herrup R., Neerukonda S. N., Vassell R., Bentley L., Eakin A. E., Erlandson K. J., Weiss C. D., Key Substitutions in the Spike Protein of SARS-CoV-2 Variants Can Predict Resistance to Monoclonal Antibodies, but Other Substitutions Can Modify the Effects. J. Virol. 96, e0111021 (2022). 10.1128/JVI.01110-21
    1. Wang R., Zhang Q., Ge J., Ren W., Zhang R., Lan J., Ju B., Su B., Yu F., Chen P., Liao H., Feng Y., Li X., Shi X., Zhang Z., Zhang F., Ding Q., Zhang T., Wang X., Zhang L., Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species. Immunity 54, 1611–1621.e5 (2021). 10.1016/j.immuni.2021.06.003
    1. Westendorf K., Wang L., Zentelis S., Foster D., Vaillancourt P., Wiggin M., Lovett E., van der Lee R., Hendle J., Pustilnik A., Sauder J. M., Kraft L., Hwang Y., Siegel R. W., Chen J., Heinz B. A., Higgs R. E., Kallewaard N., Jepson K., Goya R., Smith M. A., Collins D. W., Pellacani D., Xiang P., de Puyraimond V., Ricicova M., Devorkin L., Pritchard C., O’Neill A., Dalal K., Panwar P., Dhupar H., Garces F. A., Cohen C., Dye J., Huie K. E., Badger C. V., Kobasa D., Audet J., Freitas J. J., Hassanali S., Hughes I., Munoz L., Palma H. C., Ramamurthy B., Cross R. W., Geisbert T. W., Menacherry V., Lokugamage K., Borisevich V., Lanz I., Anderson L., Sipahimalani P., Corbett K. S., Yang E. S., Zhang Y., Shi W., Zhou T., Choe M., Misasi J., Kwong P. D., Sullivan N. J., Graham B. S., Fernandez T. L., Hansen C. L., Falconer E., Mascola J. R., Jones B. E., Barnhart B. C., LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. bioRxiv, (2022).
    1. Rothenberger S., Hurdiss D. L., Walser M., Malvezzi F., Mayor J., Ryter S., Moreno H., Liechti N., Bosshart A., Iss C., Calabro V., Cornelius A., Hospodarsch T., Neculcea A., Looser T., Schlegel A., Fontaine S., Villemagne D., Paladino M., Kaufmann Y., Schaible D., Schlegel I., Schiegg D., Zitt C., Sigrist G., Straumann M., Sacarcelik F., Wolter J., Comby M., Adler J. M., Eschke K., Nascimento M., Abdelgawad A., Gruber A. D., Bushe J., Kershaw O., Lyoo H., Wang C., Li W., Drulyte I., Du W., Binz H. K., Herrup R., Lusvarghi S., Neerukonda S. N., Vassell R., Wang W., Mangold S., Reichen C., Radom F., Knutson C. G., Balavenkatraman K. K., Ramanathan K., Lewis S., Watson R., Haeuptle M. A., Zürcher A., Dawson K. M., Steiner D., Weiss C. D., Amstutz P., van Kuppeveld F. J. M., Stumpp M. T., Bosch B.-J., Engler O., Trimpert J., Ensovibep, a novel trispecific DARPin candidate that protects against SARS-CoV-2 variants. bioRxiv, 2021.2002.2003.429164 (2022).
    1. Halwe S., Kupke A., Vanshylla K., Liberta F., Gruell H., Zehner M., Rohde C., Krähling V., Gellhorn Serra M., Kreer C., Klüver M., Sauerhering L., Schmidt J., Cai Z., Han F., Young D., Yang G., Widera M., Koch M., Werner A., Kämper L., Becker N., Marlow M. S., Eickmann M., Ciesek S., Schiele F., Klein F., Becker S., Intranasal Administration of a Monoclonal Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection. Viruses 13, 1498 (2021). 10.3390/v13081498
    1. Zost S. J., Gilchuk P., Case J. B., Binshtein E., Chen R. E., Nkolola J. P., Schäfer A., Reidy J. X., Trivette A., Nargi R. S., Sutton R. E., Suryadevara N., Martinez D. R., Williamson L. E., Chen E. C., Jones T., Day S., Myers L., Hassan A. O., Kafai N. M., Winkler E. S., Fox J. M., Shrihari S., Mueller B. K., Meiler J., Chandrashekar A., Mercado N. B., Steinhardt J. J., Ren K., Loo Y. M., Kallewaard N. L., McCune B. T., Keeler S. P., Holtzman M. J., Barouch D. H., Gralinski L. E., Baric R. S., Thackray L. B., Diamond M. S., Carnahan R. H., Crowe J. E. Jr., Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature 584, 443–449 (2020). 10.1038/s41586-020-2548-6
    1. Rappazzo C. G., Tse L. V., Kaku C. I., Wrapp D., Sakharkar M., Huang D., Deveau L. M., Yockachonis T. J., Herbert A. S., Battles M. B., O’Brien C. M., Brown M. E., Geoghegan J. C., Belk J., Peng L., Yang L., Hou Y., Scobey T. D., Burton D. R., Nemazee D., Dye J. M., Voss J. E., Gunn B. M., McLellan J. S., Baric R. S., Gralinski L. E., Walker L. M., Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody. Science 371, 823–829 (2021). 10.1126/science.abf4830
    1. Dougan M., Nirula A., Azizad M., Mocherla B., Gottlieb R. L., Chen P., Hebert C., Perry R., Boscia J., Heller B., Morris J., Crystal C., Igbinadolor A., Huhn G., Cardona J., Shawa I., Kumar P., Adams A. C., Van Naarden J., Custer K. L., Durante M., Oakley G., Schade A. E., Holzer T. R., Ebert P. J., Higgs R. E., Kallewaard N. L., Sabo J., Patel D. R., Dabora M. C., Klekotka P., Shen L., Skovronsky D. M.; BLAZE-1 Investigators , Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19. N. Engl. J. Med. 385, 1382–1392 (2021). 10.1056/NEJMoa2102685
    1. Robbiani D. F., Gaebler C., Muecksch F., Lorenzi J. C. C., Wang Z., Cho A., Agudelo M., Barnes C. O., Gazumyan A., Finkin S., Hägglöf T., Oliveira T. Y., Viant C., Hurley A., Hoffmann H. H., Millard K. G., Kost R. G., Cipolla M., Gordon K., Bianchini F., Chen S. T., Ramos V., Patel R., Dizon J., Shimeliovich I., Mendoza P., Hartweger H., Nogueira L., Pack M., Horowitz J., Schmidt F., Weisblum Y., Michailidis E., Ashbrook A. W., Waltari E., Pak J. E., Huey-Tubman K. E., Koranda N., Hoffman P. R., West A. P. Jr., Rice C. M., Hatziioannou T., Bjorkman P. J., Bieniasz P. D., Caskey M., Nussenzweig M. C., Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature 584, 437–442 (2020). 10.1038/s41586-020-2456-9
    1. Loo Y. M., McTamney P. M., Arends R. H., Abram M. E., Aksyuk A. A., Diallo S., Flores D. J., Kelly E. J., Ren K., Roque R., Rosenthal K., Streicher K., Tuffy K. M., Bond N. J., Cornwell O., Bouquet J., Cheng L. I., Dunyak J., Huang Y., Rosenbaum A. I., Pilla Reddy V., Andersen H., Carnahan R. H., Crowe J. E. Jr., Kuehne A. I., Herbert A. S., Dye J. M., Bright H., Kallewaard N. L., Pangalos M. N., Esser M. T., The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans. Sci. Transl. Med. 14, eabl8124 (2022). 10.1126/scitranslmed.abl8124
    1. Baum A., Fulton B. O., Wloga E., Copin R., Pascal K. E., Russo V., Giordano S., Lanza K., Negron N., Ni M., Wei Y., Atwal G. S., Murphy A. J., Stahl N., Yancopoulos G. D., Kyratsous C. A., Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science 369, 1014–1018 (2020). 10.1126/science.abd0831
    1. Vandeberg P., Cruz M., Diez J. M., Merritt W. K., Santos B., Trukawinski S., Wellhouse A., Jose M., Willis T., Production of anti-SARS-CoV-2 hyperimmune globulin from convalescent plasma. Transfusion 61, 1705–1709 (2021). 10.1111/trf.16378
    1. Bar-On Y. M., Goldberg Y., Mandel M., Bodenheimer O., Freedman L., Alroy-Preis S., Ash N., Huppert A., Milo R., Protection against Covid-19 by BNT162b2 Booster across Age Groups. N. Engl. J. Med. 385, 2421–2430 (2021). 10.1056/NEJMoa2115926
    1. Thompson M. G., Natarajan K., Irving S. A., Rowley E. A., Griggs E. P., Gaglani M., Klein N. P., Grannis S. J., DeSilva M. B., Stenehjem E., Reese S. E., Dickerson M., Naleway A. L., Han J., Konatham D., McEvoy C., Rao S., Dixon B. E., Dascomb K., Lewis N., Levy M. E., Patel P., Liao I. C., Kharbanda A. B., Barron M. A., Fadel W. F., Grisel N., Goddard K., Yang D. H., Wondimu M. H., Murthy K., Valvi N. R., Arndorfer J., Fireman B., Dunne M. M., Embi P., Azziz-Baumgartner E., Zerbo O., Bozio C. H., Reynolds S., Ferdinands J., Williams J., Link-Gelles R., Schrag S. J., Verani J. R., Ball S., Ong T. C., Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022. MMWR Morb. Mortal. Wkly. Rep. 71, 139–145 (2022). 10.15585/mmwr.mm7104e3
    1. Turner J. S., Kim W., Kalaidina E., Goss C. W., Rauseo A. M., Schmitz A. J., Hansen L., Haile A., Klebert M. K., Pusic I., O’Halloran J. A., Presti R. M., Ellebedy A. H., SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans. Nature 595, 421–425 (2021). 10.1038/s41586-021-03647-4
    1. Mudd P. A., Minervina A. A., Pogorelyy M. V., Turner J. S., Kim W., Kalaidina E., Petersen J., Schmitz A. J., Lei T., Haile A., Kirk A. M., Mettelman R. C., Crawford J. C., Nguyen T. H. O., Rowntree L. C., Rosati E., Richards K. A., Sant A. J., Klebert M. K., Suessen T., Middleton W. D., Wolf J., Teefey S. A., O’Halloran J. A., Presti R. M., Kedzierska K., Rossjohn J., Thomas P. G., Ellebedy A. H.; SJTRC Study Team , SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans. Cell 185, 603–613.e15 (2022). 10.1016/j.cell.2021.12.026
    1. Muecksch F., Weisblum Y., Barnes C. O., Schmidt F., Schaefer-Babajew D., Wang Z., C Lorenzi J. C., Flyak A. I., DeLaitsch A. T., Huey-Tubman K. E., Hou S., Schiffer C. A., Gaebler C., Da Silva J., Poston D., Finkin S., Cho A., Cipolla M., Oliveira T. Y., Millard K. G., Ramos V., Gazumyan A., Rutkowska M., Caskey M., Nussenzweig M. C., Bjorkman P. J., Hatziioannou T., Bieniasz P. D., Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. Immunity 54, 1853–1868.e7 (2021). 10.1016/j.immuni.2021.07.008
    1. Zhou T., Wang L., Misasi J., Pegu A., Zhang Y., Harris D. R., Olia A. S., Talana C. A., Yang E. S., Chen M., Choe M., Shi W., Teng I. T., Creanga A., Jenkins C., Leung K., Liu T., Stancofski E.-S. D., Stephens T., Zhang B., Tsybovsky Y., Graham B. S., Mascola J. R., Sullivan N. J., Kwong P. D., Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529. bioRxiv, 2021.2012.2027.474307 (2021).10.1101/2021.12.27.474307
    1. Gobeil S. M., Janowska K., McDowell S., Mansouri K., Parks R., Stalls V., Kopp M. F., Manne K., Li D., Wiehe K., Saunders K. O., Edwards R. J., Korber B., Haynes B. F., Henderson R., Acharya P., Effect of natural mutations of SARS-CoV-2 on spike structure, conformation, and antigenicity. Science 373, eabi6226 (2021). 10.1126/science.abi6226
    1. McCallum M., Czudnochowski N., Rosen L. E., Zepeda S. K., Bowen J. E., Walls A. C., Hauser K., Joshi A., Stewart C., Dillen J. R., Powell A. E., Croll T. I., Nix J., Virgin H. W., Corti D., Snell G., Veesler D., Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement. Science 375, 864–868 (2022). 10.1126/science.abn8652
    1. Charlson M. E., Pompei P., Ales K. L., MacKenzie C. R., A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J. Chronic Dis. 40, 373–383 (1987). 10.1016/0021-9681(87)90171-8
    1. Neerukonda S. N., Vassell R., Herrup R., Liu S., Wang T., Takeda K., Yang Y., Lin T.-L., Wang W., Weiss C. D., Establishment of a well-characterized SARS-CoV-2 lentiviral pseudovirus neutralization assay using 293T cells with stable expression of ACE2 and TMPRSS2. PLOS ONE 16, e0248348 (2021). 10.1371/journal.pone.0248348

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere